• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利福平、氯法齐明和B1912对已建立的小鼠足垫感染中麻风分枝杆菌生存能力的影响。

Effect of rifampin, clofazimine, and B1912 on the viability of Mycobacterium leprae in established mouse footpad infection.

作者信息

Holmes I B, Banerjee D K, Hilson G R

出版信息

Proc Soc Exp Biol Med. 1976 Apr;151(4):637-41. doi: 10.3181/00379727-151-39276.

DOI:10.3181/00379727-151-39276
PMID:772686
Abstract

Continuous dietary administration of rifampin to mice with an established Mycobacterium leprae footpad infection reduced the bacillary solid ratio, with an estimated survival half-life of 5-6 days. In rifampin-treated immunosuppressed animals the survival half-life of solid bacilli, in the absence of host immunity, was 12-13 days. Clofazimine and B1912 produced a significant effect on solid ratio only after a lag period of apparently 100 days. The rate of action was considerably slower than that of rifampin. Intermittent (once monthly) administration of both drugs produced effects similar to those of continuous administration.

摘要

对已建立麻风分枝杆菌足垫感染的小鼠持续进行饮食性利福平给药,可降低菌块比例,估计存活半衰期为5 - 6天。在利福平治疗的免疫抑制动物中,在没有宿主免疫的情况下,菌块的存活半衰期为12 - 13天。氯法齐明和B1912仅在明显长达100天的滞后期后才对菌块比例产生显著影响。其作用速度比利福平慢得多。两种药物间歇性(每月一次)给药产生的效果与持续给药相似。

相似文献

1
Effect of rifampin, clofazimine, and B1912 on the viability of Mycobacterium leprae in established mouse footpad infection.利福平、氯法齐明和B1912对已建立的小鼠足垫感染中麻风分枝杆菌生存能力的影响。
Proc Soc Exp Biol Med. 1976 Apr;151(4):637-41. doi: 10.3181/00379727-151-39276.
2
The chemotherapy of leprosy. Part 1.麻风病的化学疗法。第1部分。
Int J Lepr Other Mycobact Dis. 1990 Dec;58(4):704-16.
3
In vitro and in vivo studies of the action of rifampicin, clofazimine and B1912 on Mycobacterium marinum.利福平、氯法齐明和B1912对海分枝杆菌作用的体外和体内研究。
Chemotherapy. 1976;22(3-4):242-52. doi: 10.1159/000221931.
4
In vitro and in vivo interactions of drugs used in multidrug therapy in leprosy.麻风病联合化疗中所用药物的体外和体内相互作用。
Indian J Lepr. 1991 Apr-Jun;63(2):166-79.
5
Treatment of leprosy with clofazimine, rifampicin and Bayrena.用氯法齐明、利福平和Bayrena治疗麻风病。
Lepr Rev. 1975 Jun;46(2 Suppl):81-4. doi: 10.5935/0305-7518.19750044.
6
[Employment of a program in the leprosy campaign in Mayotte based on the use of rifampicin and clofazimine].[基于利福平与氯法齐明使用的马约特岛麻风病防治项目]
Acta Leprol. 1982 Jul-Sep(88):19-22.
7
Drug resistant-Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India.耐药性麻风杆菌——印度南部某实验室小鼠足垫研究结果
Indian J Lepr. 2002 Oct-Dec;74(4):301-12.
8
Screening of drugs for activity against Mycobacterium leprae.筛选抗麻风分枝杆菌活性的药物。
Int J Lepr Other Mycobact Dis. 1987 Dec;55(4 Suppl):836-42.
9
Dapsone drug resistance in the MDT era.多药联合治疗时代的氨苯砜耐药性。
Int J Lepr Other Mycobact Dis. 2000 Sep;68(3):323-5.
10
A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin.一株对氨苯砜、利福平、氧氟沙星和司帕沙星耐药的麻风分枝杆菌分离株。
Int J Lepr Other Mycobact Dis. 2000 Dec;68(4):452-5.

引用本文的文献

1
Assessment of TB47 as a potential novel therapeutic agent: and efficacy against .评估TB47作为一种潜在新型治疗药物:以及对……的疗效。
Antimicrob Agents Chemother. 2025 Sep 3;69(9):e0031825. doi: 10.1128/aac.00318-25. Epub 2025 Jul 23.
2
Unprecedented in vivo activity of telacebec against Mycobacterium leprae.替拉塞贝对麻风分枝杆菌具有前所未有的体内活性。
PLoS Negl Trop Dis. 2025 May 8;19(5):e0013076. doi: 10.1371/journal.pntd.0013076. eCollection 2025 May.
3
Minimal effective dose of bedaquiline administered orally and activity of a long acting formulation of bedaquiline in the murine model of leprosy.
口服乙胺丁醇的最小有效剂量和长效乙胺丁醇制剂在麻风病小鼠模型中的活性。
PLoS Negl Trop Dis. 2023 Nov 27;17(11):e0011379. doi: 10.1371/journal.pntd.0011379. eCollection 2023 Nov.